177Lu-PSMA-I&T放射性配体治疗转移性前列腺癌患者的肿瘤学结局与毒性特征
本研究纳入38例转移性前列腺癌患者(33例mCRPC、5例mHSPC),接受177Lu-PSMA-I&T放射性配体治疗,中位2个周期(范围1-7)。mCRPC中22例(69%)出现PSA下降、18例(56%)达PSA≥30%应答、11例(34%)达PSA≥50%应答,临床无进展生存期和总生存期分别为6.3和21.4个月;mHSPC全部病例PSA应答93.0%-99.9%,仅1例临床进展和肿瘤相关死亡。两组毒性均良好。
要点
- mCRPC患者中56%达PSA≥30%应答,34%达PSA≥50%应答。
- mCRPC首次RLT后临床无进展生存期6.3个月、总生存期21.4个月。
- mHSPC全部病例PSA应答93.0%-99.9%,仅1例临床进展和肿瘤相关死亡。
核心结论
- 177Lu-PSMA-I&T RLT在超过半数mCRPC患者中显示良好的PSA应答(≥30%),在全部mHSPC患者中显示极佳PSA应答。
- mHSPC和mCRPC两种情况下毒性特征均良好。
- 需进一步研究评估177Lu-PSMA-I&T RLT在转移性前列腺癌管理中的作用。
研究设计与样本
- 研究纳入38例连续转移性前列腺癌患者,其中33例为mCRPC、5例为mHSPC。
- 患者接受177Lu-PSMA-I&T放射性配体治疗,中位2个周期(范围1-7)。
- 基于PSA变化和影像学应答评估RLT应答,采用临床无进展生存期和总生存期报告肿瘤学结局。
- 毒性采用不良事件通用毒性标准(Common Toxicity Criteria for Adverse Events)评估。
主要发现
- mCRPC中22例(69%)出现任何PSA下降,18例(56%)达PSA≥30%应答,11例(34%)达PSA≥50%应答。
- mCRPC首次RLT周期后临床无进展生存期为6.3个月,总生存期为21.4个月。
- mHSPC中177Lu-PSMA-I&T RLT在全部病例中产生极佳PSA应答(93.0%-99.9%)。
- mHSPC中仅1例发生临床进展和肿瘤相关死亡。
- mHSPC和mCRPC中毒性特征均良好。
局限性
- 需进一步研究评估177Lu-PSMA-I&T RLT在转移性前列腺癌管理中的作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: This study aimed to investigate the oncological outcomes and toxicity profile of 177 Lu-PSMA-I&T radioligand therapy (RLT) in patients with metastatic castration-resistant prostate cancer (mCRPC), as well as our initial experience in metastatic hormone-sensitive prostate cancer (mHSPC). PATIENTS AND METHODS: A total of 38 consecutive patients with metastatic prostate cancer (33 mCRPC and 5 mHSPC) received 177 Lu-PSMA-I&T RLT, with a median of 2 cycles per patient (range, 1-7). Response to RLT was evaluated based on prostate-specific antigen (PSA) changes and imaging response. Clinical progression-free survival and overall survival were used to report oncological outcomes. Toxicity was assessed using the Common Toxicity Criteria for Adverse Events criteria. RESULTS: In mCRPC, 22 (69%), 18 (56%), and 11 (34%) patients achieved any PSA decline, PSA response of ≥30%, and PSA response of ≥50%, respectively. The clinical progression-free survival and overall survival after the first cycle of RLT were 6.3 and 21.4 months, respectively. In mHSPC, 177 Lu-PSMA-I&T RLT resulted in excellent PSA response (93.0%-99.9%) in all cases. Clinical progression and cancer-related mortality occurred in only 1 case. Toxicity profile was favorable in both mHSPC and mCRPC. CONCLUSIONS: 177 Lu-PSMA-I&T RLT demonstrated favorable PSA response (≥30%) in over half of the patients with mCRPC and excellent PSA response in all patients with mHSPC. Toxicity profile was favorable in both mHSPC and mCRPC settings. Further studies are needed to evaluate the role of 177 Lu-PSMA-I&T RLT in the management of metastatic prostate cancer.
引用
- Demirkol MO, Esen B, Seymen H, et al. Radioligand Therapy With 177 Lu-PSMA-I&T in Patients With Metastatic Prostate Cancer : Oncological Outcomes and Toxicity Profile. Clin Nucl Med. 2023. PMID: 37844332. doi:10.1097/RLU.0000000000004901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。